

DIASORIN LAUNCHES THE FOURTH MOLECULAR DIAGNOSTICS TEST FOR THE DETECTION OF TOXOPLASMOSIS ON ITS NEW LIAISON IAM

July 24, 2013 - Saluggia (VC) - **DiaSorin** (FTSE MIB:DIA) is pleased to announce the launch of a **new molecular diagnostic test** for the **detection of Toxoplasmosis** in the context of infectious diseases on its LIAISON IAM analyser, available on the market outside of the United States and Canada.

The **IAM Toxo** is the **fourth test** launched by the Group to **implement the panel of infectious diseases in molecular diagnostics** already composed by the assays for the detection of infections from BK Virus, Varicella Zoster and Parvovirus (IAM BKV, VZV IAM, IAM PARVO) all marketed during the past few months.

Toxoplasmosis is an infectious disease common **in the world, with around 1 billion people affected** by the infection which is caused by the parasite *Toxoplasma gondii*.

The main host of the parasite is the domestic cat, but most of the mammals and birds can be infected and become a guest in turn and then forward the infection to the man in which, once contracted, causes toxoplasmosis.

In particular Toxoplasmosis **during pregnancy can have severe consequences**. The infection can transfer from mother to foetus across the placenta and may cause foetal death or poor outcomes such as deafness, blindness, epilepsy and severe neurological disease in surviving babies.

The new IAM Toxo is a very sensitive and rapid molecular assay that provides good results in relation to the time required to perform the test when compared with alternative amplification technologies such as PCR, against which it maintains a specificity of equivalent result.

The IAM Toxo becomes **necessary for immunocompromised patients who are not fully able to fight off the infection of toxoplasmosis and for HIV-infected patients** for whom encephalitis Toxoplasmosis is one of the leading causes of death.

Paul Eros, Global Vice President for DiaSorin Molecular commented: *"The new IAM Toxo developed by DiaSorin may be used on our instrument LIAISON IAM amplification technology that uses proprietary Q-LAMP, which can provide many additional benefits compared with other amplification technologies. Our products are fast and provide real-time results and are designed to give both qualitative and quantitative results for multiplexed applications with the identification of multiple targets in a single reaction"*.

REFERENCE TABLE FOR DIASORIN PRODUCTS

Assay name	Toxoplasmosis		
Diagnosis	Infectious Diseases		
Potential market	1 billion people		
Business segment	Immunodiagnosics		Molecular Diagnostics ✓
Technology	CLIA		Extraction
	ELISA		Amplification/Detection ✓
	RIA		HLA Typing
Clinical Area	Infectious Disease		Infectious Disease ✓
	Hepatitis and Retroviruses		
	Oncology & Endocrinology		
	Bone & Mineral		Onco-hematology
	Cardiac Markers		
	GI Stool Testing		

Carlo Rosa, Chief Executive Officer of DiaSorin Group, commented: *“I am proud to announce the introduction of the DiaSorin assay for toxoplasmosis in molecular diagnostics. With the launch of our fourth test of this technology, DiaSorin strengthens its position as the Diagnostic Specialist, with particular attention to the field of infectious diseases.*

The test IAM Toxo implements our menu of infectivity in molecular diagnostics on our analyzer LIAISON IAM, a tabletop device that meets the needs of laboratories through a simple, quick and competitive.

I want to thank our team of Research and Development that continues the good work in the development pipeline that includes the launch of other molecular tests targeted at infectious diseases and onco-haematology on LIAISON IAM and which will be released between the end of this calendar year and the beginning of 2014”.

About DiaSorin

Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostics (IVD) field. For over 40 years the Company has been developing, producing and marketing reagent kits for IVD worldwide. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnosics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnosics market and new tests in the molecular diagnostics markets which identify DiaSorin Group as the IVD “diagnostics specialist”.

For additional information, please contact:

Riccardo Fava

External Relations Director - Head of IR and Media

Tel: +39.0161.487988

riccardo.fava@diasorin.it

Margherita Sacerdoti

Investor Relations Specialist

Tel: +39.0161.487456

margherita.sacerdoti@diasorin.it